Research programme: periodontitis vaccines - CSL/Sanofi PasteurAlternative Names: POD CRC-OHS
Latest Information Update: 11 Feb 2016
At a glance
- Originator CSL
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Periodontitis
Most Recent Events
- 11 Feb 2016 Preclinical development is ongoing in Australia (CSL Behring pipeline, February 2016)
- 10 Dec 2009 Preclinical trials in Periodontitis in Australia (unspecified route)